Insider · CIK 0001789490
Aaron G.L. Fletcher
ownerdirector
Files at CGTX (COGNITION THERAPEUTICS INC), ACTU (ACTUATE THERAPEUTICS, INC.), INAB (IN8BIO, INC.), LTRN (Lantern Pharma Inc.). First filing May 29, 2025, latest Jun 30, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 3
$500k bought, $500k sold
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
LTRN: Lantern Pharma Inc.
LTRNOct 9, 2026 · close 0.81
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
ACTU: ACTUATE THERAPEUTICS, INC.
ACTUOct 9, 2026 · close 0.61
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | ACTUATE THERAPEUTICS, INC. | $500k 71,428 shares | +57% | - | |
| 42Moderate | Lantern Pharma Inc. | $208k 61,613 shares | -30% | - | |
| 35Weak | Lantern Pharma Inc. | $124k 40,000 shares | -20% | - | |
| 41Moderate | Lantern Pharma Inc. | $168k 56,237 shares | -26% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 19, 2025 | CGTX COGNITION THERAPEUTICS INC | MOption exercise Common Stock | +7,729 | $0.84 | $6,492 | 56,229 | Sep 23, 2025 |
| Sep 19, 2025 | CGTX COGNITION THERAPEUTICS INC | MOption exercise Stock Option (right to buy)derivative | -7,729 | $0.00 | $0 | 0 | Sep 23, 2025 |
| Jun 27, 2025 | ACTU ACTUATE THERAPEUTICS, INC. | POpen-market purchase Common Stockindirect: Directly held by Bios 2024 Co-Invest, LP | +71,428 | $7.00 | $500k | 196,428 | Jun 30, 2025 |
| Jun 27, 2025 | ACTU ACTUATE THERAPEUTICS, INC. | POpen-market purchase Warrant (Right to Buy)derivativeindirect: Directly held by Bios 2024 Co-Invest, LP | +71,428 | $0.00 | $0 | 71,428 | Jun 30, 2025 |
| Jun 18, 2025 | CGTX COGNITION THERAPEUTICS INC | AGrant or award Common Stock | +34,000 | $0.00 | $0 | 48,500 | Jun 20, 2025 |
| Jun 13, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I QP, LP | -7,206 | $3.09 | $22k | 189,117 | Jun 13, 2025 |
| Jun 10, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I QP, LP | -3 | $3.40 | $10 | 207,419 | Jun 13, 2025 |
| Jun 13, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I, LP | -12,319 | $3.09 | $38k | 323,335 | Jun 13, 2025 |
| Jun 11, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I QP, LP | -171 | $3.40 | $581 | 207,248 | Jun 13, 2025 |
| Jun 13, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -1,903 | $3.09 | $5,880 | 49,957 | Jun 13, 2025 |
| Jun 12, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I QP, LP | -10,925 | $3.38 | $37k | 196,323 | Jun 13, 2025 |
| Jun 13, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -14,218 | $3.09 | $44k | 373,178 | Jun 13, 2025 |
| Jun 10, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I, LP | -5 | $3.40 | $17 | 354,625 | Jun 13, 2025 |
| Jun 13, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: by Bios Fund II, LP | -4,354 | $3.09 | $13k | 114,272 | Jun 13, 2025 |
| Jun 11, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I, LP | -293 | $3.40 | $996 | 354,332 | Jun 13, 2025 |
| Jun 12, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I, LP | -18,678 | $3.38 | $63k | 335,654 | Jun 13, 2025 |
| Jun 10, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -1 | $3.40 | $3 | 54,791 | Jun 13, 2025 |
| Jun 11, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -45 | $3.40 | $153 | 54,746 | Jun 13, 2025 |
| Jun 12, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -2,886 | $3.38 | $9,755 | 51,860 | Jun 13, 2025 |
| Jun 10, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -5 | $3.40 | $17 | 409,291 | Jun 13, 2025 |
| Jun 11, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -338 | $3.40 | $1,149 | 408,953 | Jun 13, 2025 |
| Jun 12, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -21,557 | $3.38 | $73k | 387,396 | Jun 13, 2025 |
| Jun 10, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -2 | $3.40 | $7 | 125,330 | Jun 13, 2025 |
| Jun 11, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -103 | $3.40 | $350 | 125,227 | Jun 13, 2025 |
| Jun 12, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -6,601 | $3.38 | $22k | 118,626 | Jun 13, 2025 |
| May 27, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I QP, LP | -3,790 | $3.05 | $12k | 213,763 | May 29, 2025 |
| May 28, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I QP, LP | -2,702 | $2.87 | $7,755 | 211,061 | May 29, 2025 |
| May 29, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I QP, LP | -3,639 | $3.03 | $11k | 207,422 | May 29, 2025 |
| May 27, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I, LP | -6,479 | $3.05 | $20k | 365,471 | May 29, 2025 |
| May 28, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I, LP | -4,620 | $2.87 | $13k | 360,851 | May 29, 2025 |
| May 29, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund I, LP | -6,221 | $3.03 | $19k | 354,630 | May 29, 2025 |
| May 27, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -1,000 | $3.05 | $3,050 | 56,467 | May 29, 2025 |
| May 28, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -714 | $2.87 | $2,049 | 55,753 | May 29, 2025 |
| May 29, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II NT, LP | -961 | $3.03 | $2,912 | 54,792 | May 29, 2025 |
| May 27, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -7,478 | $3.05 | $23k | 421,808 | May 29, 2025 |
| May 28, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -5,332 | $2.87 | $15k | 416,476 | May 29, 2025 |
| May 29, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II QP, LP | -7,180 | $3.03 | $22k | 409,296 | May 29, 2025 |
| May 27, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -2,290 | $3.05 | $6,985 | 129,163 | May 29, 2025 |
| May 28, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -1,632 | $2.87 | $4,684 | 127,531 | May 29, 2025 |
| May 29, 2025 | LTRN Lantern Pharma Inc. | SOpen-market sale Common Stockindirect: By Bios Fund II, LP | -2,199 | $3.03 | $6,663 | 125,332 | May 29, 2025 |
| May 22, 2025 | ACTU ACTUATE THERAPEUTICS, INC. | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 15,000 | May 23, 2025 |
| May 2, 2025 | INAB IN8BIO, INC. | POpen-market purchase Pre-Funded Warrantsderivativeindirect: By Bios Clinical Opportunity Fund, LP | +1,148,482 | - | - | 2,431,763 | May 7, 2025 |
| May 2, 2025 | INAB IN8BIO, INC. | JOther Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | -574,241 | - | - | 0 | May 7, 2025 |
| May 2, 2025 | INAB IN8BIO, INC. | JOther Series B Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | -574,241 | - | - | 0 | May 7, 2025 |
| Oct 4, 2024 | INAB IN8BIO, INC. | POpen-market purchase Pre-Funded Warrantsderivativeindirect: By Bios Clinical Opportunity Fund, LP | +709,040 | - | - | 1,283,281 | Oct 11, 2024 |
| Oct 4, 2024 | INAB IN8BIO, INC. | POpen-market purchase Series C Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +709,040 | - | - | 709,040 | Oct 11, 2024 |
| Oct 4, 2024 | INAB IN8BIO, INC. | DDisposition to issuer Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +574,241 | - | - | 0 | Oct 11, 2024 |
| Oct 4, 2024 | INAB IN8BIO, INC. | AGrant or award Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +574,241 | - | - | 574,241 | Oct 11, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.